ATHA

NASDAQ:ATHA

Athira Pharma

Add to Watchlist
  • Stock

0.29

+2.31%

−0.10

USD last updated 13/08 01:59:42

Last Close

0.38

12/08 20:42

Market Cap

126.10M

Beta: 2.82

Volume Today

51.22K

Avg: 246.55K

PE Ratio

−1.03

PFCF: −1.30

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheime...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -1.2-1-0.8-0.6-0.4-0.22019-09-302021-05-132022-11-102024-05-092025-02-27

    Revenue (Estimate*)

    0.000.000.010.010.012019-09-302021-05-132022-11-102024-05-092025-02-27

    *Estimate based on analyst consensus